West Pharma EPS Jumps 22 Percent in Q2

West Pharmaceutical Services (NYSE:WST), a global manufacturer of drug packaging and delivery systems for the pharmaceutical and healthcare industries, reported Q2 2025 earnings on July 24, 2025. The key news was a significant beat on both GAAP revenue and non-GAAP EPS. Adjusted earnings per share (EPS) were $1.84, outpacing the $1.51 analyst estimate (non-GAAP). Revenue reached $766.5 million, surpassing GAAP expectations of $726.1 million. Management also raised its full-year 2025 outlook for both net sales and adjusted diluted earnings per share. Overall, the quarter was marked by broad-based growth, margin improvement, and strong customer demand for the company’s proprietary products. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. West Pharmaceutical Services develops packaging and delivery systems used in the storage and administration of injectable drugs. Its products range from rubber stoppers and seals for vials, to advanced auto-injectors and wearable drug delivery devices for complex therapies. The company’s customer base includes biotech, pharmaceutical, and generic drug makers across the globe.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool